The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: A retrospective analysis

Anesthesia and Analgesia

Volumn 108, Issue 2, 2009, Pages 448-455

  Guzzetta, Nina A ^a,c   Evans, Faye M ^a   Rosenberg, Eli S ^b   Fazlollah, Tom M ^a   Baker, Michael J ^a   Wilson, Elizabeth C ^a   Kaiser, Anna M ^a   Tosone, Steven R ^a   Miller, Bruce E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Children's Healthcare of Atlanta at Egleston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CREATININE; HEPARIN; PROTAMINE; HEMOSTATIC AGENT;

AGE; ARTICLE; CARDIOPULMONARY BYPASS; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; CONGENITAL HEART MALFORMATION; HEART SURGERY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MORTALITY; PATHOPHYSIOLOGY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; THROMBOSIS; TREATMENT OUTCOME;

APROTININ; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; HEART DEFECTS, CONGENITAL; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; INFANT, NEWBORN; INTRAOPERATIVE COMPLICATIONS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME;

EID: 59649118193     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e318194007a     Document Type: Article

References (23)

1. Kovesi T, Royston D. Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 2003;84:2-10
2. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P, Nadel A, Bonney SL, Kleinfield R. A multicenter, double-blind, placebocontrolled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44
3. D'Errico CC, Shayevitz JR, Martindale SJ, Mosca RS, Bove EL. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996;83:1193-9
4. Mossinger H, Dietrich W, Braun SL, Jochum M, Meisner H, Richter JA. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003;75:430-7
5. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65
6. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006;46:327-38
7. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9
8. Bayer Healthcare Pharmaceuticals communication (Leverkusen, Germany and West Haven, CT, USA): Available at: www.trasylol. com; www.pharma.bayer.com; www.bayerscheringpharma.de/ trasylol/en, www.bayerhealthcare.com/trasylol/en.
9. Davies MJ, Allen A, Kort H, Weerasena NA, Rocco D, Paul CL, Hunt BJ, Elliott MJ. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg 1997;63:497-503
10. Miller BE, Tosone SR, Tam VK, Kanter KR, Guzzetta NA, Bailey JM, Levy JH. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998;66:535-41
11. Arnold DM, Fergusson DA, Chan AKC, Cook RJ, Fraser GA, Lim W, Blajchman MA, Cook DJ. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth Analg 2006;102:731-7
12. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg 2002;123:110-8
13. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 2004;8:R204-R12
14. Elliot MJ, Allen A. Aprotinin in paediatric cardiac surgery. Perfusion 1990;5:73-6
15. Costello JM, Backer CL, de Hoyos A, Binns HJ, Mavroudis C. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg 2003;75:1261-6
16. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991;5:467-74
17. Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, Regnier O, Legrand Y, Caen JP. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991;66:633-7
18. Dietrich W, Mossinger H, Spannagl M, Jochum M, Wendt P, Barankay A, Meisner H, Richter JA. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20
19. Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998;66:153-8
20. Penkoske PA, Entwistle LM, Marchak BE, Seal RF, Gibb W. Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg 1995;60:S529-S32
21. D'Errico CC, Munro HM, Bove EL. Pro: the routine use of aprotinin during pediatric cardiac surgery is a benefit. J Cardiothorac Vasc Anesth 1999;13:782-4
22. Mitchell JD, Grocott HP, Phillips-Bute B, Mathew JP, Newman MF, Bar-Yosef S. Cytokine secretion after cardiac surgery and its relationship to postoperative fever. Cytokine 2007;38:37-42
23. Madhok AB, Ojamaa K, Haridas V, Parnell VA, Pahwa S, Chowdhury D. Cytokine response in children undergoing surgery for congenital heart disease. Pediatr Cardiol 2006; 27:408-13